Mepact

Mifamurtide, the active ingredient in Mepact, is an immunostimulant (antineoplastic) presented as a 1 mg per vial lyophilized powder for intravenous infusion use. It is indicated for high‑grade, non‑metastatic osteosarcoma after complete surgical resection, where it is administered as part of adjuvant therapy to improve disease‑free survival.

GNH USA supplies Mepact as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing for clinical oncology programs, including academic and private institutions, and supporting regulatory compliance for cross‑border distribution.

Mepact (mifamurtide) is used as an immunotherapy for osteosarcoma, acting through innate immune activation.

- High‑grade, non‑metastatic osteosarcoma (adjuvant setting): improves disease‑free survival after complete surgical resection.

Mepact may cause a range of adverse reactions during and after infusion.

Common Side Effects: - Fever: transient elevation of body temperature during infusion. - Chills: shaking or shivering episodes. - Nausea: mild to moderate upset stomach. - Vomiting: occasional emesis post‑infusion. - Fatigue: generalized tiredness. - Hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Cytokine release syndrome: systemic inflammatory response. - Severe hypotension requiring vasopressors. - Acute respiratory distress: difficulty breathing during infusion.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for potential complications.

- Infusion reactions: monitor vital signs during and after administration. - Hepatic function: assess liver enzymes prior to each cycle. - Infection risk: defer treatment in patients with active severe infections. - Pediatric use: adjust monitoring as children may experience heightened cytokine responses. - Pregnancy and lactation: safety unknown; avoid use unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepact may interact with other agents that affect immune function or hemodynamics.

Major Interactions (Avoid): - Live vaccines: concurrent administration may cause uncontrolled immune activation. - Known hypersensitivity to excipients: avoid to prevent severe allergic reactions. - Other immunostimulants: may amplify cytokine release syndrome.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor coagulation parameters due to potential platelet activation. - Nephrotoxic drugs: assess renal function as cytokine surge can affect kidney perfusion. - Concurrent antineoplastic agents: watch for overlapping toxicities, especially hepatic and hematologic effects.